New Diagnostic tool for Lung Cancer
Since Indiana and Kentucky are the two highest ranked states for Lung cancer, this new report is promising.
Researchers recently reported at a cancer conference about a new test that can evaluate elevated blood levels of the protein human aspartyl (asparaginyl) ß-hydroxylase (HAAH) and it offers promise as an additional diagnostic tool for lung cancer.
They stated when used in conjunction with CT scanning, the HAAH serum ELISA might be able to facilitate an earlier diagnosis of lung cancer and increase the rate of survival.
Elevated levels of HAAH cannot confirm whether a person has lung cancer but can be used as a routine screening test for recommending further diagnostic evaluation. This is similar to the way most cancer biomarker tests, like prostate-specific antigen or carcinoembryonic antigen, are meant to work.
Statistically there will be approximately 213,000 individuals living in the United States diagnosed with lung cancer in 2007 and it will also be the underlying cause of more than 160,000 deaths.
Better outcomes could be achieved with earlier diagnosis.
The researches say the 5-year survival for lung cancer is only 15% but could be boosted to 50% when the diagnosis is made when the patient still has localized disease.
This HAAH serum ELISA test therefore has great promise as an additional diagnostic tool for lung cancer but will only be utilized if it is cost effective and accepted by the third party payers.
Researchers recently reported at a cancer conference about a new test that can evaluate elevated blood levels of the protein human aspartyl (asparaginyl) ß-hydroxylase (HAAH) and it offers promise as an additional diagnostic tool for lung cancer.
They stated when used in conjunction with CT scanning, the HAAH serum ELISA might be able to facilitate an earlier diagnosis of lung cancer and increase the rate of survival.
Elevated levels of HAAH cannot confirm whether a person has lung cancer but can be used as a routine screening test for recommending further diagnostic evaluation. This is similar to the way most cancer biomarker tests, like prostate-specific antigen or carcinoembryonic antigen, are meant to work.
Statistically there will be approximately 213,000 individuals living in the United States diagnosed with lung cancer in 2007 and it will also be the underlying cause of more than 160,000 deaths.
Better outcomes could be achieved with earlier diagnosis.
The researches say the 5-year survival for lung cancer is only 15% but could be boosted to 50% when the diagnosis is made when the patient still has localized disease.
This HAAH serum ELISA test therefore has great promise as an additional diagnostic tool for lung cancer but will only be utilized if it is cost effective and accepted by the third party payers.
posted by Anonymous at 6:05 AM
0 Comments:
Post a Comment
<< Home